Life ScienceCompany
Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility Ownership
Who owns Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility?
Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility is owned by BioNTech SE. It was acquired on July 19, 2021.
Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility Business Overview
Where is Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility headquartered?
Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility is headquartered in Gaithersburg, Maryland.
What sector is Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility in?
Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility is a life science company.
Life Science M&A Summary in 2021
Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2021. The largest life science acquisition in 2021 was Pharmaceutical Product Development - which was acquired by Thermo Fisher Scientific for $17.4B.
Join Mergr to view all 392 acquisitions of life science companies in 2021, including 46 acquisitions by private equity firms, and 346 by strategics.